Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Friday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX stock opened at $6.50 on Friday. The company has a 50 day moving average price of $6.27 and a 200 day moving average price of $2.95. Brooklyn ImmunoTherapeutics has a fifty-two week low of $5.10 and a fifty-two week high of $8.31. The stock has a market capitalization of $382.37 million, a PE ratio of -2.86 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Dividend Announcement

The company also recently announced a monthly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, March 14th were paid a $0.0862 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.03 annualized dividend and a dividend yield of 15.90%. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is currently -45.37%.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.